Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients by Inayat U Rahman et al.
Rahman et al. Nutrition Journal 2015, 14:13
http://www.nutritionj.com/content/14/1/13RESEARCH Open AccessLower hypoglycemic but higher antiatherogenic
effects of bitter melon than glibenclamide in type
2 diabetic patientsInayat U Rahman1*, Rooh Ullah Khan2, Khalil Ur Rahman3 and Mohammad Bashir4Abstract
Objective: Since antiquity bitter melon has been in use for treating diabetes but clinical trials show conflicting
results about its usefulness. The present study aims to asses and compare the hypoglycemic and antiatherogenic
effects as well as the safety of two different doses of bitter melon with glibenclamide.
Methods: A total of 95 participants were randomized into 3 groups; group I and group II received bitter melon
(2 g/day and 4 g/day respectively) and group III received glibenclamide (5 mg/day) for 10 weeks. Glycemic control
and antiatherogenic effects were determined by assessing glycohemoglobin (HbA1-c), fasting plasma glucose (FPG),
2 hour oral glucose tolerance test (OGTT), plasma sialic acid (PSA), systolic blood pressure (SBP), blood lipids and
atherogenic index at different time periods.
Results: Compared to baseline, mean reduction in HbA1-c at the endpoint was significant among patients of group
I, group II and group III (p≤ 0.05, p ≤ 0.02 and p < 0.005 respectively) and same was the case for FPG (p ≤ 0.05,
p < 0.04, p < 0.003 respectively), but the improvement in 2 hour OGTT was significant only in group III (p < 0.03). The
decrease in PSA was observed only among group I and group II with the later showing significant reduction from
baseline (p < 0.01). In group III, the level slightly increased. Parameters including blood lipids, atherogenic index,
body weight and SBP improved among patients of group I and group II but deteriorated among group III patients.
Conclusions: Our study concludes that bitter melon has a weaker hypoglycemic effect but ameliorates the
diabetes associated cardiovascular (CV) risk factors more effectively than glibenclamide.
Trial registration: The trial was registered with Naseer Teaching Hospital Clinical Trials Registry number GU2014492233.
Keywords: Bitter melon, Glibenclamide, Type 2 diabetics, Glycemic control, Cardiovascular risk factorsIntroduction
In developing world, herbal remedies are gaining popular-
ity and 80-85% of their population relies upon alternative
system of medicine. More than 7000 medicinal plants are
currently in use by different cultures of the world to treat
various conditions and almost 800 plants in the Asian
subcontinent are shown to possess hypoglycemic activity
[1,2]. Among the various medicinal plants, bitter melon
(family: Cucurbitaceae, genus: Momordica, species: Char-
antia) is the most popular and commonly used herb for* Correspondence: marwax07@yahoo.com
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unless otherwise stated.treating diabetes [3]. There is uncertainty about the exact
location of its origin, but it is cultivated in many tropical
regions of India, Pakistan, China as well as South America
and East Africa. Although, all parts of the plant have been
shown to possess antidiabetic activities, the most com-
monly used part is the fruit pulp which is used in the form
of juice or dried powder [4,5]. A cluster of animal studies
have documented the hypoglycemic effects of bitter melon
fruit extracts [6-9]. Studies also indicate that glucose low-
ering effects of bitter melon fruit extract are comparable
to some oral hypoglycemic agents used in the initial man-
agement of diabetes [10,11]. Bitter melon is believed to
exert its hypoglycemic effect through multiple mecha-
nisms involving the stimulation or inhibition of the keyl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the key enzymes of hexose monophosphate pathway [12],
increases the utilization of peripheral and skeletal muscle
glucose [6,7], prevents glucose uptake by intestine [13-15],
inhibits gluconeogenesis [12,16] and adipocytes differenti-
ation [17] and normalizes the islet β cells [18,19].
As compared to animal studies, only few clinical trials
have been conducted so far regarding the hypoglycemic
potential of bitter melon and majority of these studies
lack proper control and have conflicting results [20-22].
Indeed, Diabetes United Kingdom (UK) has warned the
people regarding the use of bitter melon capsules be-
cause of lack of information about its safety and recom-
mended dose [23]. Because of the frequent use of
processed bitter melon in the treatment of diabetes mel-
litus and the lack of information about its efficacy and
safety, there is an urgent need to conduct a clinical trial
comparing the hypoglycemic and/or antiatherogenic po-
tential of bitter melon with oral hypoglycemic agent
(OHA) and the present study is an attempt to evaluate
and compare the antidiabetic and antiatherogenic effects
as well as the safety of two different doses of bitter
melon with glibenclamide in type 2 diabetic patients.
Methods
A total of 112 type 2 diabetic patients, attending the
medical ward of Naseer Teaching Hospital, Gandhara
University, Peshawar, KPK, Pakistan, who had been pre-
viously managed with diet/exercise only for recently di-
agnosed type 2 diabetes (≤2 years) from the study
screening were enrolled into the study and 95 were
assigned to one of the 3 treatment groups (Table 1). Re-
cruitment for the study was conducted according to the
declaration of Helsinki (1997). The study protocol was
approved by Gandhara University medical ethics com-
mittee. The volunteer patients of type 2 diabetes were
explained the research protocol and their written in-
formed consents obtained for the study. Participants
were informed of their right to withdraw from the study
at any time. They were advised not to take any drug
without prior permission from investigator. PatientsTable 1 Baseline characteristics of type 2 diabetic patients
Parameters Bitter melon 2 g/day
(Group I)
N 30
Sex, M/F 21/9 (70/30)
Age (y) 51.90±10.50
Time since diagnosis of diabetes (yr)
0-1 22 (73)
≤2 8 (27)
BMI (Kg/m2) 25.2±1.70were screened for eligibility for study entry according to
the criteria presented in below.
Eligibility criteria for participation in the study
Inclusion criteria
Type 2 diabetes mellitus (M/F) as diagnosed according
to World health Organization 1999 (WHO) criteria
FPG 126-240 mg/dl
Age 30-70 years
Normal Renal Function Tests
Normal liver Function Tests
Exclusion criteria
Previous use of antidiabetic drugs
Presence of cancer
Menopausal status or pregnancy
Use of contraceptives




The present study is randomized, double blind, parallel
group trial consisted of 2 weeks run-in period during
which the patients received placebo and included reinfor-
cement of lifestyle education to obtain fasting plasma glu-
cose level between 126-240 mg/dl (7-13 mmol/l). After
exclusion of 17 subjects who did not meet the inclusion
criteria, a total of 95 diabetic subjects were randomized
into 3 groups; group I received bitter melon 2 g/day (n =
32), group II received bitter melon 4 g/day (n = 33) and
group III received glibenclamide 2.5 mg/day (n = 30) for
10 weeks. 5 patients violated the study protocols (2 each
in group I and II and 1 in group III) and did not complete
the study.
Bitter melon powder was given in the form of capsules
(1000 mg) and glibenclamide in the form of tablets.
Doses of bitter melon used in this study are based on
previously reported improvement of blood glucose levelsBitter melon 4 g/day Glibenclamide (5 mg/day)
(Group II) (Group III)
31 29
20/11 (65/35) 18/11 (62/38)
52±11.40 52.20±8.70
24 (77) 20 (70)
7 (23) 9 (30)
25.7±2.40 25±2.20
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were used as placebo for bitter melon and glibenclamide
respectively.
Procedures and measurements
All participating subjects reported fasting in the morning
after 12-14 h overnight fast and omission of any morn-
ing doses of glucose lowering agents. Venous blood sam-
ples were collected without the use of a tourniquet.
After screening, the baseline visit (randomization) was
scheduled 2 weeks later. FPG and PSA were measured at
baseline and then after every week for 10 weeks. HbA1-c,
blood lipids and SBP were measured at baseline and at the
end point. These parameters were measured with reagents
prepared by Boehringer Mannheim (Lewis, UK). Meas-
urement of HbA1c was carried out through Fast ion-
exchange resin separation method.
Therapeutic goal was to achieve statistically significant
decreases in HbA1-c levels while observing the changes
in PSA. Secondary end points include mean changes in
FPG, OGTT and blood lipids.
Source and preparation of bitter melon
Unripe bitter melon fresh fruit obtained from Agricul-
ture farm Sarai Naurang (Lakki Marwat) was washed
thoroughly with water, cut open and the seeds removed.
The fruits were then processed by modifying the method
proposed by Fuangchan et al. [22]. The juice was ex-
tracted from the fruit pulps by using electric juicer
which was then tested for microbial contamination and/
or the presence of heavy metals by the Departments of
Basic Medical Sciences and Pharmaceutical Sciences re-
spectively, Gandhara College of Pharmacy, Gandhara
University, Peshawar, Pakistan. The non-contaminated
juice (460 ml/Kg) was frozen at −20°C and then freeze


















Figure 1 Effect of bitter melon and glibenclamide on HbA1-c level. G
Group III = Glibenclamide (2.5 mg/day). *p≤ 0.05 compared to baseline, ¤p≤juice. When tested for the active constituent charantin
and protein content as described earlier [24,25], the
mean yields were 0.085% and 0.110 mg/g of powder
respectively.Statistical methods
Results are expressed as means ± SD. Data analysis were
carried out using SPSS and a Р ≤ 0.05 was taken as sta-
tistically significant. Non-parametric statistical methods
were used due to unsymmetrical distribution of most
variables. Comparisons among groups were made by dif-
ferences of mean changes in HbA1-c, FPG, OGTT, PSA,
blood lipids, body weight and SBP using Mann-Whitney
U-test and Krushkal-Wallis one-way ANOVA test.Results
Table 1 shows the general characteristics of study
groups (after cutting outliers) at baseline. There were
no significant differences in the mean values of vari-
ables among the groups. Subjects in all the groups were
overweight with the males higher in ratio than females.
The proportion of subjects who completed the study
was 94% each for group I and II and 97% for group III.Changes in glycohemoglobin
Compared to baseline, we observed significant decreases
in the mean levels of HbA1-c at the end point among
patients of group I, group II and group III with the later
showing greater reduction than the formers (8.25 ± 0.70
vs. 7.40 ± 0.50, p ≤ 0.05; 8.30 ± 0.55 vs. 7.15 ± 0.60, p ≤
0.02; 8.45 ± 0.60 vs. 6.90 ± 0.75, p < 0.005 respectively).
Between groups comparison at the end point revealed




roup I = Bitter melon (2 g/day); Group II = Bitter melon (4 g/day);
0.01 compared to baseline, †p≤ 0.05 compared to group III at week 10.
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PSA showed a trend towards decreased level from base-
line to endpoint among patients of group I and group II,
but the temporal pattern of these reductions was different
among the groups. In group I, the level decreased from
74 ± 8.10 mg/dl at baseline to 68 ± 6.70 mg/dl at the end-
point (p < 0.08), whereas in group II, statistically signifi-
cant decrease occurred from 75.30 ± 8.20 mg/dl at
baseline to 63 ± 6.70 mg/dl at the endpoint (p < 0.01).
Moreover, the decrease was more rapid in group II
compared to group I. In group III, the level slightly de-
teriorated and rose from 73.90 ± 7.20 mg/dl at baseline
to 75.10 ± 5.20 mg/dl at the endpoint (p ≤ 0.11). The
mean difference was significant at the endpoint be-
tween group II and group III (P ≤ 0.05) (Figure 2).Changes in fasting plasma glucose
FPG levels significantly decreased from baseline to end-
point in group I, group II and group III with the group
III showing greater reduction (146 ± 13.40 mg/dl vs.
133.70 ± 11.50 mg/dl, p ≤ 0.05; 141.60 ± 15.20 mg/dl vs.
126.40 ± 11.90 mg/dl, p < 0.04; 143.50 ± 18.40 mg/dl
vs. 117 ± 10.30 mg/dl, p < 0.003 respectively). The mean
difference was significant (p ≤ 0.05) between group I
and group III at the endpoint (Table 2).Oral glucose tolerance test and changes in blood glucose
levels
The changes observed in 2 hour plasma glucose levels
after OGTT were non-significant both in group I and
group II (241.30 ± 15.60 vs. 235 ± 19.50, p < 0.16; 247 ±
21.90 vs. 240.70 ± 25.10, p < 0.10 respectively). However, a
significant change in 2 hour plasma glucose level after
OGTT was observed in group III (255.60 ± 26.30 vs.
















Figure 2 Changes in PSA overtime. Group I = Bitter melon (2 g/day); Gro
*p≤ 0.05 compared to baseline, ¤p≤ 0.01 compared to baseline, †p≤ 0.05 cin 2 hour plasma glucose levels between groups revealed
no significant difference (Table 2).Effect on blood lipids and atherogenic index
The mean changes occurred in blood lipids of groups I, II
and III from baseline to endpoint are shown in Table 2.
Total cholesterol changed by −3.75 mg/dl, −4.10 mg/dl
and +1.50 (p < 0.10, p < 0.06 and p < 0.12 respectively), low
density lipoprotein-cholesterol changed by −3.20 mg/dl,
−5.10 mg/dl and +1.70 mg/dl (p ≤ 0.06, p < 0.01 and p <
0.12 respectively), high density lipoprotein-cholesterol
changed by +1.85 mg/dl, +3.60 mg/dl and −2.10 mg/dl
(p < 0.11, p < 0.09 and p < 0.13 respectively), and triglycer-
ide changed by −3.40 mg/dl, −13.80 mg/dl and +7.40 mg/
dl (p ≤ 0.07, p ≤ 0.05 and p < 0.08 respectively). Unlike
group III, the ratios of TC/HDL and LDL/HDL improved
in group I and group II from baseline to endpoint but the
mean difference between groups was non-significant
(Table 2).Effect on systolic blood pressure and body weight
The mean reduction in SBP from baseline to endpoint
was non-significant in group I (p ≤ 0.06) but significant in
group II (p < 0.05). In group III, there was a slight increase
in SBP (p < 0.20). The mean change in body weight from
baseline to endpoint among patients of group I, group II
and group III was −1.85 Kg (p < 0.09), −3.10 Kg (p < 0.06)
and +1.60 Kg (p < 0.25) respectively (Table 2).
During the course of the present study, few gastrointes-
tinal (GI) disturbances occurred among patients receiving
bitter melon. These include heartburn and diarrhea (9.3%,
6.2% and 15.15%, 9% in group I and group II respectively).
We did not observe GI disturbances among patients re-
ceiving glibenclamide, but 6.6% of the patients suffered





up II = Bitter melon (4 g/day); Group III = Glibenclamide (2.5 mg/day).
ompared to group III at week 10.
Table 2 Effect of bitter melon and glibenclamide on clinical/metabolic variables of study groups
Variables Baseline Endpoint (week 10)
FPG (mg/dl)
Bitter melon 2 g/day (Group I) 146±13.40 133.70±11.50*†
Bitter melon 4 g/day (Group II) 141.60±15.20 126.40±11.90*
Glibenclamide 5 mg/day (Group III) 143.50±18.40 117±10.30¤
2 h post OGTT plasma glucose (mg/dl)
Bitter melon 2 g/day (Group I) 241.30±15.60 235±19.50
Bitter melon 4 g/day (Group II) 247±21.90 240.70±25.10
Glibenclamide 5 mg/day (Group III) 255.60±26.30 229.40±20.80*
T C (mg/dl)
Bitter melon 2 g/day (Group I) 218.25±10.70 214.50±14.50
Bitter melon 4 g/day (Group II) 227.10±15.50 221±11.60
Glibenclamide 5 mg/day (Group III) 220.50±11.10 222±10.80
LDL-c (mg/dl)
Bitter melon 2 g/day (Group I) 149.70±18.20 146.50±11.50
Bitter melon 4 g/day (Group II) 154±15.50 148.90±16.40
Glibenclamide 5 mg/day (Group III) 146.80±10.30 148.50±12.35
HDL-c (mg/dl)
Bitter melon 2 g/day (Group I) 48.15±4.90 50±3.50
Bitter melon 4 g/day (Group II) 47.60±5.70 51.20±4.20
Glibenclamide 5 mg/day (Group III) 48.10±5.50 45±4.90
T G (mg/dl)
Bitter melon 2 g/day (Group I) 163.20±17.50 159.80±16.70
Bitter melon 4 g/day (Group II) 168±13.40 154.20±11.80*
Glibenclamide 5 mg/day (Group III) 165.50±20.50 172.90±18.40
T C/HDL-c ratio
Bitter melon 2 g/day (Group I) 4.53±1.10 4.29±1.20
Bitter melon 4 g/day (Group II) 4.77±1.60 4.31±1.35
Glibenclamide 5 mg/day (Group III) 4.58±1.15 4.93±1.50
LDL-c/HDL-c ratio
Bitter melon 2 g/day (Group I) 3.10±1.35 2.93±1.10
Bitter melon 4 g/day (Group II) 3.23±1.52 2.89±1.31
Glibenclamide 5 mg/day (Group III) 3±1.47 3.30±1.20
SBP (mmHg)
Bitter melon 2 g/day (Group I) 139±8.10 135.50±11.90
Bitter melon 4 g/day (Group II) 144.80±23.70 133.10±14.30*
Glibenclamide 5 mg/day (Group III 136.20±12.24 135.50±10.50
Weight (Kg)
Bitter melon 2 g/day (Group I) 69.50±10.70 67.65±11.32
Bitter melon 4 g/day (Group II) 73.90±12.20 70.80±10.50
Glibenclamide 5 mg/day (Group III 68.40±8.30 70±11.90
*p≤0.05 compared to baseline; ¤p≤0.01 compared to baseline; †p≤0.05 compared to group III at week 10.
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To the best of our knowledge, only few randomized,
controlled clinical trials have been conducted to evaluateand compare the hypoglycemic effect of bitter melon fruit
pulps with commonly used oral hypoglycemic agents, but
most of these studies have conflicting results about the
Table 3 Unwanted effects of bitter melon and








Hyperacidity/Heart burn 3 (9.3) 5 (15.1) 1 (3.4)
Anorexia 5 (16.6) 5 (15.1) 3 (10.3)
Nausea 2 (6.6) 3 (9.6) 1 (3.4)
Diarrhoea 1 (3.3) 2 (6.4) -
Appetite 2 (6.6) 5 (16.1) 3 (10.3)
Abdominal discomfort 1 (3.3) 1 (3.2) -
Central Nervous System
Headache 4 (13.3) 9 (29) 5 (17.2)
Dizziness 2 (6.6) 1 (3.20 2 (6.8)
Dermatological
Skin rashes - 2 (6.4) 1 (3.4)
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formation about its effect on diabetes associated CV risk
factors [20,26]. Results of the present study indicate sig-
nificant reductions in HbA1-c levels from baseline to end-
point among patients receiving bitter melon (group I,
group II) and glibenclamide (group III) with the group III
showing greater reduction. At the endpoint, the difference
in mean reduction of HbA1-c levels between the groups
was non-significant. These results are in agreement with
the recent findings by Fuangchan et al. [22] which show a
significant decrease in fructosamine level of bitter melon
treated type 2 diabetics but in contrast with the previous
study reporting a non-significant decline in HbA1-c levels
of type 2 diabetics after taking bitter melon extract for
3 months [27]. However, the study has been criticized
due to lack of information about the standardization of
bitter melon product. Differences in the processing of
bitter melon preparation may affect the activity and the
hypoglycemic effect of aqueous extract of fruit is re-
ported to be more than the dried fruit powder [21].
A significant decrease in PSA level from baseline to
endpoint was observed only in a group receiving bitter
melon 4 g/day. Sialic acid is present in glycoconjugates
as terminal monosaccharide and is a possible risk factor
for CVD in diabetics as well as in general population
[28-30]. Its high plasma level reflects the ongoing ath-
erosclerotic process [31]. Earlier, we have shown signifi-
cant improvement in PSA and cholesterol levels of type
2 diabetics following bitter melon fruit juice and the fail-
ure of dried powder of bitter melon 2 g/day (group I) to
produce significant reduction in PSA confirms the hy-
pothesis that aqueous extract of the bitter melon fruit is
more efficacious than the dried fruit powder [21]. Al-
though, we do not have a solid reason but it might be pos-
sible that drying and further processing during powderpreparation may cause loss and/or inactivation of some
active ingredients notably the polypeptide-p. The group
receiving glibenclamide showed a slight increase in the
level of PSA from baseline to endpoint. There is a direct
relationship between sialic acid and blood lipids and the
increase in PSA level may be the result of unfavorable ef-
fects of glibenclamide on blood lipids.
The mean changes in 2 hour plasma glucose levels
after OGTT were non-significant whereas the changes
in FPG levels were significant in group I and II. In group
III, the mean changes in 2 hour plasma glucose after
OGTT and FPG levels from baseline to endpoint were
significant. The previous findings by Srivastava et al. [21]
and Fuangchan et al. [22] also showed significant reduc-
tions in FPG levels in bitter melon treated subjects. Re-
cently conducted randomized, clinical control trial report
no significant changes either in OGTT or FPG levels of
type 2 diabetics after taking bitter melon for 4 weeks
[22]. However, the use of hot air oven for drying fruit
pulp (60°C for 24 hours) may caused denaturation and
inactivation of polypeptide-P and other compounds
thereby decreasing the hypoglycemic effect of bitter
melon [25,32]. In addition, the lower charantin con-
tent/g of the dried fruit pulp in the study by Fuangchan
et al. [22] than the present study might be due to the
use of heat for drying purposes.
Unlike the group receiving glibenclamide in which the
blood lipid levels deteriorated, the groups receiving bit-
ter melon showed favorable changes in the blood lipid
levels from baseline to endpoint, but did not reach the
statistical significance except the triglyceride level of a
group receiving bitter melon 4 g/day (group II). Moreover,
the mean TC/HDL ratio was found to be low among pa-
tients of group I and group II than group III. TC/HDL
ratio is more sensitive and specific index of CV risk
than TC alone, specially with values >6 [33]. According
to Framingham Heart Study, total cholesterol-to-HDL
ratio of 5 signifies for men an average risk of heart dis-
ease whereas for women, a ratio of 4.4 signifies an average
risk [34]. Treatment with bitter melon 2 g/day and 4 g/
day was also associated with decreases in body weight and
SBP from baseline to endpoint, but the decrease was sig-
nificant only in the body weight of a group receiving bitter
melon 4 g/day. These wanted effects were not observed
with glibenclamide that rather exerted deteriorating effect.
Controversies about the hypoglycemic effects of BM
exist due to differences in the processing of its prepar-
ation and will continue to exist until a validated standard-
ized method for the preparation of BM formulation is not
developed. The present study favors the hypoglycemic
effect of bitter melon among type 2 diabetics at the
dose of 2 g/day and 4 g/day however, the glycemic con-
trol was poor compared to glibenclamide. In contrast,
the effect on diabetes associated CV risk factors was
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the BM to be less hypoglycemic but more antiathero-
genic than glibenclamide.
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